Author: BusinessWire

Novel MAPS™ vaccine is designed to induce both a B-cell and T-cell protective immune response to multiple, highly conserved staphylococcal protein antigens
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biotechnolog…

Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors

Maverick’s lead candidate TAK-186 (f…

— FDA RMAT Designation for RP-L201 to Help Expedite Development and Registration —

— Enrollment Complete in Phase 1/2 Clinical Trial of RP-L201 for the Treatment of LAD-I —
CRANBURY, N.J.–(BUSINESS WIRE)–$RCKT #GeneTherapy–Rocket Pharmaceuticals, …

Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors

Maverick’s lead candidate TAK-186 (f…

— FDA RMAT Designation for RP-L201 to Help Expedite Development and Registration —

— Enrollment Complete in Phase 1/2 Clinical Trial of RP-L201 for the Treatment of LAD-I —
CRANBURY, N.J.–(BUSINESS WIRE)–$RCKT #GeneTherapy–Rocket Pharmaceuticals, …

PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17)

Interim efficacy and safety evaluation of the CALM Stud…

PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17)

Interim efficacy and safety evaluation of the CALM Stud…

Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors

Maverick’s lead candidate TAK-186 (f…

– Primary and secondary endpoints were met, key exploratory endpoints supported clinical benefit in Phase 3 study of omidubicel in patients with hematologic malignancies; BLA submission anticipated in fourth quarter of 2021-

— Omidubicel commercial p…

Novel MAPS™ vaccine is designed to induce both a B-cell and T-cell protective immune response to multiple, highly conserved staphylococcal protein antigens
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biotechnolog…